{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:22:41Z","timestamp":1793931761556,"version":"4.8.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The aim of this study was to determine whether clinical outcome of patients with methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MRSA) bacteraemia was correlated with vancomycin susceptibility of the corresponding strains.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study on MRSA bacteraemia was performed at a teaching hospital between January 1998 and October 2005 by linking vancomycin susceptibility profiles of patients' isolates with hospitalization data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 20 out of 209 MRSA bacteraemia patients were treated with vancomycin for at least 5 days with adequate trough levels, and fulfilled the study's inclusion and exclusion criteria. Twenty-two\n                      <jats:italic>S. aureus<\/jats:italic>\n                      isolates from these patients' blood cultures were identified as MRSA, including two\n                      <jats:italic>hetero<\/jats:italic>\n                      -VISA from separate patients and two VISA with vancomycin MIC of 4 mg\/L from one patient. Between patients who showed 'good' vancomycin response and patients who did not, there was a significant difference (p &lt; 0.01) in their corresponding MRSAs' vancomycin susceptibility expressed by 'area under curve' (AUC) of population analysis. Significant correlations were found between AUC and initial vancomycin therapeutic response parameters of 'days till afebrile' (\n                      <jats:italic>r<\/jats:italic>\n                      = 0.828, p &lt; 0.01) and 'days till CRP \u2266 30% of maximum' (\n                      <jats:italic>r<\/jats:italic>\n                      = 0.627, p &lt; 0.01)\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study results caution healthcare personnel that early consideration should be given to cases with a poor vancomycin treatment response that could signify the involvement of MRSA with reduced susceptibility to vancomycin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1476-0711-6-13","type":"journal-article","created":{"date-parts":[[2007,10,30]],"date-time":"2007-10-30T01:41:34Z","timestamp":1193708494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections"],"prefix":"10.1186","volume":"6","author":[{"given":"Hui-min","family":"Neoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutaka","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoko","family":"Oguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longzhu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,10,30]]},"reference":[{"key":"112_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10156-004-0307-5","volume":"10","author":"C Gemmell","year":"2004","unstructured":"Gemmell C: Glycopeptide resistance in Staphylococcus aureus: is it a real threat?. J Infect Chemother. 2004, 10: 69-75. 10.1007\/s10156-004-0307-5","journal-title":"J Infect Chemother"},{"key":"112_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s15010-004-4124-7","volume":"32","author":"C Ruef","year":"2004","unstructured":"Ruef C: Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection. 2004, 32: 315-327. 10.1007\/s15010-004-4124-7","journal-title":"Infection"},{"key":"112_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(97)07324-8","volume":"350","author":"K Hiramatsu","year":"1997","unstructured":"Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I: Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogenously resistant to vancomycin. Lancet. 1997, 350: 1670-1673. 10.1016\/S0140-6736(97)07324-8","journal-title":"Lancet"},{"key":"112_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1248\/bpb.26.876","volume":"26","author":"T Iwamoto","year":"2003","unstructured":"Iwamoto T, Kagawa Y, Kojima M: Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull. 2003, 26: 876-879. 10.1248\/bpb.26.876","journal-title":"Biol Pharm Bull"},{"key":"112_CR5","first-page":"1659","volume-title":"Hospital epidemiology and Infection Control","author":"TC Horan","year":"2004","unstructured":"Horan TC, Gaynes RP: Surveillance of nosocomial infections. Hospital epidemiology and Infection Control. Edited by: Mayhall CG. 2004, 1659-702. Philadelphia: Lippincott Williams & Wilkins, 3,","edition":"3"},{"key":"112_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00000542-197810000-00003","volume":"49","author":"WD Owens","year":"1978","unstructured":"Owens WD, Felts JA, Spitznagel EL: ASA physical status classification: a study of consistency of ratings. Anesthesiology. 1978, 49: 239-243. 10.1097\/00000542-197810000-00003","journal-title":"Anesthesiology"},{"issue":"4","key":"112_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1086\/381202","volume":"38","author":"BP Howden","year":"2004","unstructured":"Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML: Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Inf Dis. 2004, 38 (4): 521-528. 10.1086\/381202.","journal-title":"Clin Inf Dis"},{"key":"112_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/jac\/40.1.135","volume":"40","author":"K Hiramatsu","year":"1997","unstructured":"Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997, 40: 135-136. 10.1093\/jac\/40.1.135","journal-title":"J Antimicrob Chemother"},{"key":"112_CR9","first-page":"282","volume-title":"Manual of Clinical Microbiology","author":"WE Kloos","year":"1995","unstructured":"Kloos WE, Bannerman TL: Staphylococcus and Micrococcus. Manual of Clinical Microbiology. Edited by: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. 1995, 282-298. Washington, DC: American Society for Microbiology Press, 6,","edition":"6"},{"key":"112_CR10","volume-title":"CLSI document M100-S16. Wayne, PA","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2006","unstructured":"Clinical and Laboratory Standards Institute (CLSI): Performance Standards for Antimicrobial Susceptibility Testing. 16th Informational Supplement. CLSI document M100-S16. Wayne, PA. 2006,"},{"key":"112_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jac\/47.4.399","volume":"47","author":"M Wootton","year":"2001","unstructured":"Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, Macgowan AP: A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother. 2001, 47: 399-403. 10.1093\/jac\/47.4.399","journal-title":"J Antimicrob Chemother"},{"key":"112_CR12","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","volume":"42","author":"G Sakoulas","year":"2004","unstructured":"Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004, 42: 2398-2402. 10.1128\/JCM.42.6.2398-2402.2004","journal-title":"J Clin Microbiol"},{"key":"112_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1248\/yakushi.121.621","volume":"121","author":"M Tanaka","year":"2001","unstructured":"Tanaka M, Orii T, Kobayashi H, Hirono S: Examination of factors affecting efficacy and adverse effect, for the retrospective study of vancomycin hydrochloride (VCM). Japanese Yakugaku Zasshi. 2001, 121: 621-629. 10.1248\/yakushi.121.621.","journal-title":"Japanese Yakugaku Zasshi"},{"key":"112_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1086\/381093","volume":"38","author":"PG Charles","year":"2004","unstructured":"Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML: Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Inf Dis. 2004, 38: 448-51. 10.1086\/381093.","journal-title":"Clin Inf Dis"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-0711-6-13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T18:30:58Z","timestamp":1630434658000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/1476-0711-6-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,30]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["112"],"URL":"https:\/\/doi.org\/10.1186\/1476-0711-6-13","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13485033.14862160","asserted-by":"object"}]},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,30]]},"assertion":[{"value":"30 July 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"13"}}